Amylyx Pharmaceuticals Reports $43.4 Million Net Loss in Q2 2026

Amylyx Pharmaceuticals, Inc. reported a net loss of $43.4 million for the second quarter of 2026, a 5% increase from the $41.4 million loss recorded in the same period of 2025. The company's total operating expenses rose to $45.7 million, up from $42.9 million year-over-year, driven primarily by a 40% increase in selling, general, and administrative expenses, which reached $21.9 million. Research and development expenses decreased by 13% to $23.8 million, largely due to a significant reduction in costs associated with the AMX0035 program following its discontinuation. The company’s accumulated deficit increased to $836.1 million as of June 30, 2026, compared to $751.4 million at the end of 2025.

In terms of financial position, Amylyx reported current assets of $256.3 million, a decrease from $323.7 million at the end of 2025. Cash and cash equivalents fell sharply to $49.3 million from $226.7 million, while marketable securities increased to $201.4 million from $90.3 million. The company’s total liabilities decreased slightly to $25.4 million from $27.4 million, reflecting a reduction in accrued expenses. The company indicated that its existing cash, cash equivalents, and marketable securities are expected to fund operations into 2028, although this estimate is subject to change based on various factors.

Strategically, Amylyx is advancing its clinical pipeline, focusing on avexitide, which is currently undergoing a Phase 3 clinical trial known as LUCIDITY for post-bariatric hypoglycemia (PBH). The trial has completed patient enrollment, and topline data is expected to be announced in the third quarter of 2026, with a potential commercial launch in 2027 if approved. Additionally, the company is developing AMX0035 for Wolfram syndrome and AMX0114 for amyotrophic lateral sclerosis (ALS), with ongoing clinical trials for both products. The company has also entered into a collaboration agreement with Gubra A/S to develop a novel GLP-1 receptor antagonist, AMX0318.

Operationally, Amylyx has seen fluctuations in its research and development expenses, with a notable increase in costs related to avexitide, which rose by 54% to $19.3 million for the first half of 2026. The company has also expanded its workforce to support pre-commercialization activities, resulting in increased personnel-related costs. As of June 30, 2026, the company had 111.4 million shares outstanding, reflecting ongoing stock option exercises and vesting of restricted stock units.

Looking ahead, Amylyx faces several risks and uncertainties, including the need for additional funding to support its clinical development efforts and the potential for regulatory challenges. The company has acknowledged that it may require substantial additional capital to continue its operations and pursue its business objectives. Furthermore, the evolving regulatory landscape and potential changes in healthcare policies could impact the commercialization of its product candidates. The company remains focused on advancing its clinical programs while navigating these challenges.